Legislation· Sep 2024Sponsored by Brad R. Wenstrup (R)
BIOSECURE Act
Bars federal agencies and grant recipients from buying biotech from companies controlled by foreign adversaries.
Tradeoff
Would have restricted federal contracts and grants to five named Chinese biotech companies and others deemed security risks. Cost federal agencies minimal administrative overhead to enforce the ban.
What's in it
Cost between zero and $500,000 over the 2024-2034 period, with no estimated impact on revenues or deficits.
The $500,000 or less in federal costs reflects only the administrative overhead for the government to enforce the contract ban and conduct annual reviews—the policy's real impact is the restriction of federal funding access to five foreign-owned biotech companies and any others added to the list annually.
The House passed this 306-81 on September 9, 2024 under . The bill expired with the 118th Congress without Senate action.
House
Introduced
(May 10, 2024)
House
Committee on Oversight and Accountability(May 10, 2024)
The bill went to more than one committee at the same time.
House
The committee voted to send it to the floor
Reported 40 - 1(May 15, 2024)
House
On Motion to and Pass, as Amended
Passed(Roll #402 · Sep 9, 2024)
306 yeanay 81Senate
Received from the House
on Homeland Security and Governmental Affairs(Sep 10, 2024)
- Raja Krishnamoorthi (D-IL)
- John R. Moolenaar (R-MI)
- Anna G. Eshoo (D-CA)
- Neal P. Dunn (R-FL)
- Seth Moulton (D-MA)
- Elise M. Stefanik (R-NY)
- Donald G. Davis (D-NC)
- Ashley Hinson (R-IA)
- Elissa Slotkin (D-MI)
- Stephanie I. Bice (R-OK)
- Josh Gottheimer (D-NJ)
- Thomas R. Suozzi (D-NY)
- Darin LaHood (R-IL)
- Mark E. Green (R-TN)
Passage votes· Sep 9, 2024· 118th Congress · 2023–2025